[S5A]GexIVA[1,2]

General Information


DRACP ID  DRACP06171

Peptide Name   [S5A]GexIVA[1,2]

Sequence  TCRSAGRYCRSPYDRRRRYCRRITDACV

Sequence Length  28

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides α9α10nAChR inhibitor



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  α9α10nAChR

Affinity  IC50=27 nM (Blocking α9α10nAChR)

Mechanism  Specifically block the α9α10nAChR

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys2<--->Cys9; Cys20<--->Cys27

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C139H231N55O40S4

Absent amino acids  EFHKLMNQW

Common amino acids  R

Mass  392270

Pl  10.4

Basic residues  9

Acidic residues  2

Hydrophobic residues  4

Net charge  7

Boman Index  -14544

Hydrophobicity  -121.79

Aliphatic Index  31.43

Half Life 
  Mammalian: 7.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  4720

Absorbance 280nm  174.81

Polar residues  12

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN112010959A

Patent Title  Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.